Article thumbnail

An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease

By Sony Mathews, Ashley Reid, Chenlu Tian and Qiang Cai

Abstract

Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. Proton pump inhibitors (PPIs) are the most effective medication for both initial treatment and maintenance therapy of GERD. Pantoprazole, a first-generation PPI, was approved by the FDA in 2000 for the treatment of erosive esophagitis associated with GERD. It has been used in more than 100 different countries worldwide. It is one of the few PPIs available in multiple forms: a delayed-release oral capsule, oral suspension, and intravenous. Pantoprazole been shown to improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality of life more effectively than histamine-2 receptor antagonists. Evaluated in over 100 clinical trials, pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low incidence of drug interactions. It has also been shown to be safe and effective in special patient populations, such as the elderly and those with renal or moderate liver disease

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3108659
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis. Dig Dis Sci.
  2. A review of its pharmacological properties and therapeutic use in acid-related disorders.
  3. (2004). Acute interstitial nephritis due to pantoprazole. Ann Pharmacother.
  4. American Gastroenterological Association Medical Position Satement on the management of gastroesophageal refluz disease.
  5. Clinical experience with pantoprazole in gastroesophageal reflux disease. Clin Ther. 2000;22:1169–1185; discussion 1149–1150.
  6. (1998). Clinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican Pantoprazole Study Group. Rev Gastroenterol Mex.
  7. (1997). Clinical tolerability of pantoprazole compared with ranitidine and famotidine. International Clinicial Practice Series.
  8. (2002). Comparable efficacy of pantoprazole 40 mg vs omeprazole
  9. Comparable efficacy of pantoprazole and omeprazole to prevent relapse
  10. (2002). Comparison of the efficacy of panctoprazole vs nizatidine in the treatment of erosive oesophagtitis: a randomized active-controlled, double0blind study. Aliment Pharmacol Ther.
  11. (1999). Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Methods Find Exp Clin Pharmacol.
  12. (1997). Efficacy and tolerability of pantoprazole versus ranitidine and famotidine in patients with gastro-oesopghageal reflux disease: multicentre, open, randomised, control studies. International Clinical Practice Series.
  13. (2002). Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate. Dis Esophagus.
  14. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, doubleblind comparative trial–the EMANCIPATE study.
  15. (2008). Impact of PPIs on patient focused symptomatology in GERD. Ther Clin Risk Manag.
  16. (2009). International validation of a health-related quality of life questionnaire in patients with erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther.
  17. (2007). International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. Digestion.
  18. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastrooesophageal reflux disease.
  19. (2006). Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. Dig Dis Sci.
  20. (2007). Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag.
  21. (2007). Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging.
  22. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
  23. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial.
  24. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
  25. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial.
  26. (2007). Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. Aliment Pharmacol Ther.
  27. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease.
  28. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
  29. Pantoprazole 40 mg relieves primary reflux symptoms more rapidly than omeprazole MUPS 20 mg in patients with severe GERD symptomatology.
  30. (1995). Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther.
  31. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther.
  32. (2007). Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Investig.
  33. Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine.
  34. (2001). Pantoprazole versus lansoprazole in French patients with reflux esophagitis. Gastroenterol Clin Biol.
  35. Pantoprazole-induced acute interstitial nephritis.
  36. (2006). Pantoprazole-induced thrombocytopenia. Ann Pharmacother.
  37. (2007). Pantoprazole: a proton pump inhibitor with oral and intravenous formulations. Expert Rev Gastroenterol Hepatol.
  38. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
  39. Prevalence of gastro-oesophageal reflux disease in general practice. Dtsch Med Wochenschr.
  40. (2004). Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther.
  41. (1997). Proton pump inhibitors and acid-related diseases.
  42. Proton pump inhibitors: an update of their clinical use and pharmacokinetics.
  43. (1999). Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).
  44. (1993). Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?
  45. randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5–11 years) with symptomatic gastroesophageal reflux disease.
  46. (2006). randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr (Phila).
  47. Restoration of acid secretion following treatment with proton pump inhibitors.
  48. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis – a 2-year follow-up. Aliment Pharmacol Ther.
  49. Safety of potent gastric acid inhibition.
  50. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther.
  51. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
  52. (1998). The impact of gastroesophageal reflux disease on health-related quality of life.
  53. (1943). The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.
  54. (1996). Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther.
  55. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.
  56. Use of proton pump inhibitors and risk of osteoporosis-related fractures.